Resume. The search for new drugs with cytoprotective and anti-ischemic activity is an urgent task of modern pharmacology. These properties are necessary for the complex protection of renal parenchyma during organ preservation operations (renal resection), most often carried out in conditions of thermal ischemia. Only the combined use of modern highly effective drugs and the skill of an operating surgeon can prevent the development of acute renal injury (AKI) due to pinching of renal vessels. The aim of this study was to investigate the nephroprotective effects of a combination of a peptide mimicking the a-helix B of erythropoietin (pHBSP) and infliximab in ischemic reperfusion damage to the kidneys. Methods. The experiment was conducted on 50 white laboratory male Wistar rats weighing 280-320 g. Animals were injected with a peptide mimicking the a-helix B of erythropoietin (pHBSP) and infliximab. Under anesthesia, atraumatic vascular clamps were applied to the left renal pedicle for 40 minutes, nephrectomy on the right. Functional samples and laboratory tests were performed 5 minutes and 72 hours after reperfusion. Results. As a result of the study, it was shown that using a combination of the peptide simulating a-helix B erythropoietin (pHBSP) and infliximab in ischemic-reperfusion kidney injury showed significantly more pronounced nephroprotective effects than using the peptide mimicking a-helix B erythropoietin or infliximab in the mono mode. Conclusion.The results of the study show the promise of combined use of peptide simulating a-helix B erythropoietin (pHBSP) and infliximab in order to correct ischemic-reperfusion kidney injuries.

Purpose: Due to the severe clinical course and the high socio-economic significance of acute kidney injury, the issue of methods for diagnosing and treating this pathology is on the agenda of the scientific community around the world. One of the most specific biomarkers of acute kidney injury is KIM-1. KIM-1 is an apical transmembrane protein of the proximal renal tubule. Elevated levels of KIM-1 in a model of ischemia-reperfusion injury of the kidneys correlate with inflammation and fibrosis in histological studies. The aim of this work was to study the protective effects of a combination of a peptide mimicking the -helix B of erythropoietin (pHBSP) and infliximab on the epithelium of nephron tubules in ischemia-reperfusion injury of the kidneys. Methods: The experiment was conducted on 80 white laboratory male Wistar rats weighing 280320 g. Animals were injected with a peptide mimicking the -helix B of erythropoietin (pHBSP) and infliximab. Under anesthesia, atraumatic vascular clamps were applied to the left renal pedicle for 40 minutes, nephrectomy on the right. Within 12 hours after reperfusion, urine samples were collected for laboratory studies. Results: According to the results of the experiment, it was found that the use of a combination of a peptide mimicking the -helix B of erythropoietin (pHBSP) and infliximab more effectively protected the epithelium of the nephron tubules from damage during ischemia-reperfusion injury of the kidneys than the administration of a peptide mimicking the -helix B of erythropoietin or infliximab in mono mode. Conclusion: The results of the study clearly substantiate the prospects for the combined use of a peptide mimicking the -helix B of erythropoietin (pHBSP) and infliximab to protect the nephron tubule epithelium from ischemia-reperfusion injury.